Bayer bags swift OK for Nubeqa in metastatic prostate cancer
pharmaphorum
AUGUST 8, 2022
The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC). billion) blockbuster.
Let's personalize your content